What is the role of vandetanib in the treatment of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

A randomized, double-blind, phase III trial assessed the use of vandetanib, a once-daily oral inhibitor of vascular EGFR and EGFR signaling. [172] This second-line therapy did not meet the primary end point of statistically significant progression-free survival. However, the combination of vandetanib (100 mg/d) plus pemetrexed (500 mg/m2) produced a significantly higher objective response rate and a significant delay in time to worsening of symptoms compared with placebo. The combination also had an acceptable safety profile. This indication is not yet approved by the FDA.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!